Your browser doesn't support javascript.
loading
Vascular cutaneous manifestations of COVID-19 and RNA viral pathogens: a systematic review.
Karch, Jamie L; Okorie, Chiamaka L; Maymone, Mayra B C; Laughter, Melissa; Vashi, Neelam A.
Affiliation
  • Karch JL; Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Okorie CL; Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Maymone MBC; Department of Dermatology, The Warren Alpert Medical School, Brown University, Providence, RI, USA.
  • Laughter M; Department of Dermatology, New York University, New York, NY, USA.
  • Vashi NA; Department of Dermatology, Boston University School of Medicine, Boston, MA, USA.
Clin Exp Dermatol ; 49(4): 313-324, 2024 Mar 21.
Article in En | MEDLINE | ID: mdl-37936304
ABSTRACT

BACKGROUND:

COVID-19, the widely recognized and highly contagious respiratory tract infection, has had a substantial impact on the field of dermatology since its emergence in 2019. SARS-CoV-2, the causative virus of COVID-19, is classified as an RNA virus. Various skin-related symptoms have been reported in patients with COVID-19, most notably the distinctive purple-red acral rash resembling chilblain lesions, commonly referred to as 'COVID toe'; similarly, skin-related symptoms have been observed in connection with other RNA viruses.

OBJECTIVES:

To explore the relationship between RNA viruses and their associated vascular cutaneous manifestations vs. those observed in patients infected with SARS-CoV-2.

METHODS:

A systematic literature review was conducted using PubMed and medical subject heading terms related to RNA viruses and related skin manifestations.

RESULTS:

In total, 3994 patients diagnosed with COVID-19 presenting with skin rashes were included. Chilblain-like lesions were most frequently observed (30.2%), followed by erythematous maculopapular/morbilliform rashes (9.1%) and urticarial rashes (4.7%). Of 8362 patients diagnosed with RNA viruses, more than half of the skin findings reported were erythematous/maculopapular/morbilliform rashes (52.3%), followed by unspecified (11.3%) and purpuric rashes (10.6%).

CONCLUSIONS:

When comparing RNA viral infections with COVID-19 infection, we observed similarities in the reported skin manifestations and their presumed pathways, with many implicated in the proinflammatory response. Owing to the wide range of cutaneous symptoms associated with RNA viruses and our currently limited understanding of the underlying mechanisms, additional research is warranted to investigate the pathology behind viral-induced skin lesions.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA Viruses / Skin Diseases / Chilblains / COVID-19 Type of study: Systematic_reviews Limits: Humans Language: En Journal: Clin Exp Dermatol Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA Viruses / Skin Diseases / Chilblains / COVID-19 Type of study: Systematic_reviews Limits: Humans Language: En Journal: Clin Exp Dermatol Year: 2024 Type: Article Affiliation country: United States